Navigation Links
Mayo Clinic offers newly approved treatment for acid reflux disease

    VIDEO ALERT: Additional video resources, including excerpts from an interview with Dr. C. Daniel Smith describing the device and procedure, are available on the Mayo Clinic News Blog.

JACKSONVILLE, Fla. Mayo Clinic in Florida will be one of the first health care institutions in the United States to offer a newly approved device to treat gastroesophageal reflux disease (GERD). The condition, also known as acid reflux disease, can lead to serious health problems.

The U.S. Food and Drug Administration (FDA) approved the device and treatment procedure on March 22 for patients with GERD who continue to have chronic reflux symptoms despite taking medication.

Mayo Clinic in Florida expects to offer the new treatment immediately, says C. Daniel Smith, M.D., chair of the Surgery Department at Mayo Clinic in Florida, and an internationally recognized expert on the treatment of GERD.

Dr. Smith is experienced in using the system because Mayo Clinic in Florida was one of only 14 centers nationally that participated in a clinical trial that led to the FDA's approval of the device.

"Mayo has been a leader in the treatment of esophageal diseases, especially GERD, and we are pleased to be offering this new treatment to our patients immediately," he says.

GERD is a condition in which liquid, or food, in the stomach flows back up into the esophagus due to the inability of a ring of muscle between the lower esophagus and the top of the stomach to close properly.

If drugs aimed at neutralizing the acid in the stomach fails to prevent GERD, an operation designed to correct the mechanical defect is considered. But between 1.5 million and 2 million patients of those patients could benefit from treatment that is much less complex than current surgical options, Dr. Smith says.

"The new system will offer a long-needed treatment option for a large group of underserved patients," he says.

The results of the clinical study that led to approval of the device have not yet been published. But "the data presented to the FDA revealed striking results when compared to other GERD treatments that have been investigated over the past 20 years," Dr. Smith says. "The system offers effective control of GERD with limited side effects and thus far an excellent safety record."

The implanted device is a ring of tiny magnetic titanium beads that is wrapped around the junction between the stomach and esophagus, serving as a mechanical augmentation of the lower esophageal sphincter (the ring of muscle). The magnetic attraction between the beads is strong enough to keep the sphincter closed to refluxing acid, but weak enough so that food can pass through it into the stomach, Dr. Smith says. The device can be implanted using minimally invasive surgery methods.

Dr. Smith performs about 200 GERD-related surgeries a year and has been involved with many new treatments over the past several decades. "I expect this device to be a game changer for the treatment of GERD in select patients who have failed management with drugs," says Dr. Smith.

Ken DeVault, M.D., chair of the Department of Internal Medicine at Mayo Clinic in Florida, also participated in these studies. "I have many patients who are searching for something more than medication for their reflux, but have been hesitant to undergo a traditional reflux surgery," he says. "I think this procedure may well be a very attractive option for that group."

Contact: Kevin Punsky
Mayo Clinic

Related medicine news :

1. Mayo Clinic launches whole genome breast cancer study
2. Clinical news alert from the American Academy of Orthopaedic Surgeons
3. Clinical insight improves treatment with new lung cancer drug
4. First targeted nanomedicine to enter human clinical studies
5. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
6. Early clinical data show galeterone safe, effective against prostate cancer
7. Cleveland Clinic study shows bariatric surgery improves, reverses diabetes
8. Stephanie R. Wilson, MD, to be presented with the Joseph H. Holmes Clinical Pioneer Award
9. Mayo Clinic researchers building melanoma vaccine to combat skin cancer
10. Mayo Clinic review: Blood pressure drug effective for treating PTSD-related nightmares
11. Standardized outcome measures proposed for asthma clinical research
Post Your Comments:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: